Evidence-Based Approach to the Management of Sinonasal Cancers

PROGRAM DESCRIPTION: Focus: We will present an overview of the contemporary management of sinonasal cancers from diagnosis to survivorship. We will present a summary of updates in imaging and pathology, including newly identified histological subtypes such as SMARC-B1 deficient carcinoma, NUT carcinoma. We will discuss broad principles and differences in treatment by tumor groups, including squamous cell carcinoma, minor salivary gland tumors, neuroendocrine cancers including olfactory neuroblastomas and sinonasal undifferentiated carcinomas. We will discuss recent advances in multimodality therapy (including chemotherapy, targeted therapy, immunotherapy and radiotherapy), strategies for organ preservation and quality of life considerations. We will present an algorithm for evidence-based decision-making to develop a comprehensive treatment plan for patients with sinonasal cancers. Lastly, we will provide an overview of survivorship surveillance and toxicity monitoring. We will use case-based discussion to illustrate nuances in treatment.

Sinonasal cancers are rare but aggressive malignancies that are poorly understood. Diagnosis, staging and treatment are rapidly evolving. The paucity of clinical trials and evidence-based, published guidelines pose a challenge to identifying best practice. Moreover, sinonasal malignances and their treatment may impact critical head and neck organs resulting in functional impairments. Multi-disciplinary treatment is paramount to improving survival and quality of life. This presentation will focus on multimodality therapy and updates in diagnosis, treatment, and survivorship. We believe this will be informative for both trainees and practicing surgeons.